About the Journal

Aims and Scope

Spinal Cord is a specialised, international journal that has been publishing spinal cord related manuscripts since 1963. It appears monthly, online and in print, and accepts contributions on spinal cord anatomy, physiology and management of injury and disease. Spinal Cord is multi-disciplinary and publishes contributions on basic science, clinical and applied studies, psychology and epidemiology of spinal disorders. It publishes high quality original papers and topical reviews.

Spinal Cord’s sister journal Spinal Cord Series and Cases publishes case reports, small case series, letters to the editor, book reviews and material of national or local interest. For more information, please see the aims and scope of Spinal Cord Series and Cases.

Journal Details

Editor-in-Chief:
Professor Lisa Harvey
The University of Sydney, Australia
lisa.harvey@sydney.edu.au

Post-Acceptance

Impact factor: 1.870 (2016 Journal Citation Reports, Thomson Reuters, 2017)

Frequency: 12 issues a year

Abstracted in:

BIOBASE/Current Awareness in Biological Sciences
Biological Abstracts
BIOSIS
British Medicine
Current Contents
Current Contents/Clinical Medicine
EMBASE/Excerpta Medica
MEDLINE/Index Medicus
NMLUIS
Science Citation Index Expanded
Scopus
UMI
**Patient consent**

For all articles that include information or clinical photographs relating to individual patients, where those patients could be identified by readers in any way, written and signed consent to publish must be obtained from each patient and a written letter of consent should be mailed or faxed to the editorial office. Please indicate where the illustration can be cropped if identifiable features are not essential to the illustration. In cases where consent has not been obtained and recognizable features may appear, it will be necessary to retouch the illustration to mask the eyes or otherwise render the individual ‘officially unrecognizable’.

**Clinical Trials**

**IMPORTANT MESSAGE: Mandatory requirement starting 1st January 2018**

From 2018: All clinical trials starting on or after January 1st 2018 **MUST** be registered **BEFORE** the first participant is randomised to be accepted for publication in *Spinal Cord*. A clinical trial is any study in which participants are allocated to a treatment. See [here](#) for more details.

---

**ARTICLE TYPE SPECIFICATIONS**

<table>
<thead>
<tr>
<th>ARTICLE DESCRIPTION</th>
<th>ABSTRACT</th>
<th>WORD LIMIT</th>
<th>TABLES/FIGURES</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Original Articles</strong></td>
<td>Structured abstract,</td>
<td>3,500 words max*</td>
<td>Up to 3 Figures</td>
</tr>
<tr>
<td>Please see ‘Preparation of</td>
<td>max 250 words</td>
<td></td>
<td>and 4 Tables*</td>
</tr>
<tr>
<td>Original Articles’ below for</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>further details.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Priority will be given to</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>original research that</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>contains prospectively</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>collected data. Retrospective</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>chart audits, reliability</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>studies and surveys are a</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>low publication priority</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>unless authors can</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>demonstrate that the study</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>is particularly novel and</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>would be of wide interest to</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>readers.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Review</strong></td>
<td>Structured abstract,</td>
<td>4,500 words max*</td>
<td>Up to 3 Figures</td>
</tr>
<tr>
<td>Comprehensive analysis of</td>
<td>max 250 words</td>
<td></td>
<td>and 2 Tables*</td>
</tr>
<tr>
<td>specific topics. Proposals</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>for reviews may be</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>submitted; however, authors</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>should only send an outline</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>of the proposal paper for</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>initial consideration. Both</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>solicited and unsolicited</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>reviews will undergo peer</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>review prior to acceptance.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Priority will be given to</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>reviews with clearly stated</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PICOs in which the results</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>are presented in forest plots</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>with meta-analyses as</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>appropriate.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Editorials</strong></td>
<td>No abstract required</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Proposals for Editorials</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>may be submitted; however</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>authors should only send an</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>outline of the proposed</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Editorial for initial</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>consideration.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Comment and Editorial Page</strong></td>
<td>No abstract required</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Only by invitation from the</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Editor-in-Chief.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Unless these restrictions prevent authors from conveying key messages. If these restrictions are exceeded then authors need to provide an explanation in their covering letter and be aware that they may be asked to reduce the number of Figures, Tables and length of the manuscript.
Please note that original articles must contain the following components. All sections of the article text where noted (*) must be included in a single article file and uploaded in Word format. Tables may be included in the article text or uploaded as separate editable files. Figures must be uploaded as separate figure files and not included in the article file. Please see below for further details.

- Cover letter
- Title page (excluding acknowledgements)*
- Structured Abstract*
- Keywords*
- Introduction*
- Methods*
- Results*
- Discussion*
- Acknowledgements*
- Conflicts of Interest*
- References*
- Figure legends*
- Tables
- Figures

Clinical trials must be registered and reported according to CONSORT guidelines (see details in the Editorial Policies).

**Cover Letter:** The uploaded cover letter must state that the material is original research, has not been previously published and has not been submitted for publication elsewhere while under consideration. If the manuscript has been previously considered for publication in another journal, please include the previous reviewer comments to help expedite the decision by the Editorial team. The cover letter must also include a statement about potential or real conflicts of interest (see Editorial Policy section).

**Title Page:** The title page should bear the title of the paper, the full names of all the authors and their affiliations, together with the name, full postal address, telephone and fax numbers and e-mail address of the author to whom correspondence and offprint requests are to be sent (this information is also asked for on the electronic submission form). The title page must also contain a Conflicts of Interest statement (see Editorial Policy section). The following rules should be followed:

- The title should be brief, informative, of 150 characters or less.
- The running title should consist of no more than 50 letters and spaces. It should be as brief as possible, convey the essential message of the paper and contain no abbreviations.
- Authors should disclose the sources of any support for the work, received in the form of grants and/or equipment and drugs.
- If authors regard it as essential to indicate that two or more co-authors are equal in status, they may be identified by an asterisk symbol with the caption 'These authors contributed equally to this work' immediately under the address list.

**Reporting of demographic and neurological details:**

Demographic data should be reported as mean and standard deviation, or median and interquartile range depending on whether the data are skewed or not. If data are to be grouped, then authors are encouraged to follow the recommendations of DeVivo et al.¹ For example, age should be grouped in 15 year increments: 0–15, 16–30, 31–45, 46–60, 61–75, 76+. For pediatric SCI the following increments are recommended: 0–5, 6–12, 13–15, 16–21. When time since injury is grouped, 5 year increments should be used: <1 year, 1–5 years, 6–10 years, 11–15 years, and 5-year increments thereafter. Calendar time (years during which the study is conducted) should be grouped by either 5 or 10 year increments with years ending in 4 or 9. The severity of injury should be grouped as CI-4 ASIA Impairment Scale grade (AIS) A, B, or C; C5-8 AIS A, B, or C; T1-S5 AIS A, B, or C; AIS D at any injury level; Ventilator-dependent at any injury level or AIS grade. If data are limited, the above groups can be collapsed.

**Structured Abstract:** Original Articles must be prepared with a structured abstract designed to summarise the essential features of the paper in a logical and concise sequence under the following mandatory headings:

- **Study Design**
- **Objectives**
- **Setting (i.e. country and/or county or state)**
- **Methods**
- **Results**
- **Conclusions:** Answer (significant or not) to main question
- **Sponsorship** (where applicable)

**Keywords:** Up to six short MeSH words or phrases which best describe the paper. These will be used for indexing your paper.

**Methods:** The Methods section should contain sufficient detail, so that all experimental procedures can be reproduced. All standard procedures and outcome measures should be referenced. Methods, that have been published in detail elsewhere can be summarised with a reference to the full methodology. Authors should provide the name of the manufacturer and their location for any specifically named medical equipment or instrument. All drugs should be identified by their pharmaceutical names, and by their trade name if relevant.

**Statement of Ethics:** Where a manuscript concerns animal experimentation or the use of human volunteers, the authors should include a statement at the end of the Methods section stating: "I/we certify that all applicable institutional and governmental regulations concerning the ethical use of human volunteers/animals were followed during the course of this research" (delete inappropriate words).

**Results:** The Results section should briefly present the experimental data in text, Tables or Figures. Results presented in Tables and Figures should not be described extensively in the text. All results comparing groups should be presented as point estimates with measures of precision (eg. Between-group differences and 95% confidence intervals).

**Discussion:** The Discussion section should focus on the interpretation and the significance of the findings with concise objective comments that describe the authors’ work in relation to the work of others in the area. It should not repeat information presented in the Results section. The final paragraph should highlight the main conclusion(s), and provide some indication of the direction of future research.

**Acknowledgements:** These should be brief, and should include sources of support including sponsorship (e.g. university, charity, commercial organisation) and sources of material (e.g. novel drugs) not available commercially.

---

Conflicts of Interest: Authors must declare whether or not there are any competing financial interests in relation to the work described. This information must be included at this stage and will be published as part of the paper. Conflicts of interest should also be noted in the covering letter and included on the title page. Please see the Conflicts of Interest documentation in the Editorial Policy section for detailed information.

References: Only papers directly related to the article should be cited. Exhaustive lists should be avoided. References should follow the Vancouver format. In the text they should appear as numbers starting at one. The full details of the References should appear at the end of the paper (double-spaced) in numerical order corresponding to the order of citation in the text. Where a reference is to appear next to a number in the text, for example following an equation, chemical formula or biological acronym, citations should be written as (ref. X) and not as superscript. Example “detectable levels of endogenous Bcl-2 (ref. 3), as confirmed by western blot”.

All authors should be listed for papers with up to six authors; for papers with more than six authors, only the first six authors should be listed, followed by et al. Abbreviations for titles of medical periodicals should conform to those used in the latest edition of Index Medicus. The first and last page numbers for each reference should be provided. Abstracts and letters must be identified as such. Papers in press may be included in the list of references.

Personal communications must be allocated a number and included in the list of references in the usual way or simply referred to in the text; the authors may choose which method to use. In either case authors must obtain permission from the individual concerned to quote his/her unpublished work.

Examples:
Journal article, up to six authors:
Journal article, e-pub ahead of print:

Journal article, in press:

Complete book:

Chapter in book:

Abstract:

Correspondence:

Figure Legends: These should be brief, specific and appear on a separate manuscript page after the References section titled ‘Titles and legends to Figures’.

Tables: Tables should only be used to present essential data; they should not duplicate what is written in the text. It is imperative that tables are editable and ideally submitted in Excel format. Each must be uploaded as a separate workbook with a title or caption and be clearly labelled, sequentially. Reference to Table footnotes should be made alphabetically. Tables should not duplicate the content of the text, and should consist of at least two columns; columns should always have headings. Ensure each Table is cited within the text and in the correct order, e.g., (Table 3). Files for Tables need to be saved with one of the following file extensions: .xls / .xlsx / .ods / .doc or .docx. Please ensure that you provide a ‘flat’ file, with single values in each cell with no macros or links to other workbooks or worksheets and no calculations or functions.

For tables with bold formatting, we ask authors to provide an explanation that would be included in the table legend. In this case, as there is no scientific significance for the bold text, this would go against our journal style and we would not be able to publish the article in that format.

Figures: Figures and images should be labelled sequentially and cited in the text e.g. (Fig.1). Figures should not be embedded within the text but uploaded as separate files. Detailed guidelines for submitting artwork can be found by downloading the Artwork Guidelines. The use of three-dimensional histograms is strongly discouraged when the addition of the third dimension gives no extra information.

Artwork Guidelines: Detailed guidelines for submitting artwork can be found by downloading the Artwork Guidelines. All artwork needs to be production quality and submitted with the initial online submission. If a paper is accepted for publication and the artwork has been prepared according to the guidelines, authors will not be required to resubmit the artwork following the peer-review process.

Colour on the web: Authors who wish their articles to have FREE colour figures on the web (only available in the HTML (full text) version of manuscripts) must supply separate files as supplementary information and authors need to state in the Cover Letter at submission that they would like colour figures on the web version of their paper.

Reuse of Display Items: See the Editorial Policy section for information on using previously published Tables or Figures.

Standard abbreviations: Because the majority of readers will have experience in spinal cord medicine, the journal will accept papers which use certain standard abbreviations, without definition in the summary or in the text. Non-standard abbreviations should be defined in full at their first usage in the Summary and again at the
first usage in the text, in the conventional manner. Terms used less than four times in the text, should not be abbreviated.

**Supplementary Information:** Supplementary Information (SI) is peer-reviewed material directly relevant to the conclusion of an article that cannot be included in the printed version owing to space or format constraints. The article must be complete and self-explanatory without the SI. All SI will be posted on the journal’s website and linked to the article. Supplementary Information may consist of data files, graphics, movies or extensive tables. Please see the Artwork Guidelines for information on accepted file types. Authors should submit Supplementary Information files in a FINAL format as they are not edited, typeset or changed, and will appear online exactly as submitted. When submitting SI, authors are required to:

- Include a text summary (no more than 50 words) to describe the contents of each file.
- Identify the types of files (file formats) submitted.
- Include the text “Supplementary Information is available at Spinal Cord’s website” at the end of the article and before the references.

**Availability of Data and Materials:** Please see our Editorial Policies for information regarding data, protocols, sequences, or structures.

**House Style**

The following formatting rules should be followed:

- Text should be double spaced with a wide margin.
- All pages and lines are to be numbered. To add page numbers in MS Word, go to Insert then Page Numbers. To add line numbers go to File, Page Setup, then click the Layout tab. In the Apply to box, select Whole document, click Line Numbers then select the Add line numbering check box, followed by Continuous.
- Do not make rules thinner than 1pt (0.36mm).
- Use a coarse hatching pattern rather than shading for tints in graphs.
- Colour should be distinct when being used as an identifying tool.
- Spaces, not commas should be used to separate thousands.
- At first mention of a manufacturer, the town (and state if USA) and country should be provided.
- Statistical methods: For normally distributed data, mean (SD) is the preferred summary statistic. Relative risks should be expressed as odds ratios with 95% confidence interval. To compare two methods for measuring a variable the method of Bland & Altman (1986, Lancet 1, 307–310) should be used; for this, calculation of P only is not appropriate.
- Units: Use metric units (SI units) as fully as possible. Preferably give measurements of energy in kilojoules or MegaJoules with kilocalories in parentheses (1 kcal = 4.186kJ). Use % throughout.
- Abbreviations: On first using an abbreviation place it in parentheses after the full item. Note these abbreviations: gram g; litre l; milligram mg; kilogram kg; kilojoule kJ; megajoule MJ; weight wt; seconds s; minutes min; hours h. Do not add s for plural units.

**Language Editing**

SC is read by scientists from diverse backgrounds and many are not native English speakers. Authors should give careful thought to how their findings may be communicated clearly. Although a shared basic knowledge of the field may be assumed, please bear in mind that the language and concepts that are standard in one subfield may be unfamiliar to non-specialists. Thus, technical jargon should be avoided as far as possible and clearly explained where its use is unavoidable. Abbreviations, particularly those that are not standard, should also be kept to a minimum. The background, rationale and main conclusions of the study should be clearly explained. Titles and abstracts in particular should be written in language that will be readily intelligible to any scientist.

Authors who are not native speakers of English sometimes receive negative comments from referees or editors about the language and grammar in their manuscripts, which can contribute to a paper being rejected. To reduce the possibility of such problems, we strongly encourage authors to take at least one of the following steps:

- Have your manuscript reviewed for clarity by a colleague in whom English is his/her first language.
- Visit the English language tutorial which covers the common mistakes when writing in English.
- Using a professional language editing service where editors will improve the English to ensure that your meaning is clear and identify problems that require your attention. Two such services are provided by our affiliates Nature Research Editing Service and American Journal Experts.

Please note that the use of a language editing service is at the author's own expense and does not guarantee that the article will be selected for peer review or accepted.

**HOW TO SUBMIT**

**Pre-submission Enquiries**

Pre-submission enquiries should be sent to the editorial office: e-mail spinalcord@iscos.org.uk

**Online Submission**

We only accept manuscript submissions via our online manuscript submission system. Before submitting a manuscript, authors are encouraged to consult both our Editorial Policies and the Submission Instructions for our online manuscript submission system. Authors need to register for an account with our online manuscript system if they have not already done so. Authors will be able to monitor the status of their manuscripts online throughout the editorial process.

**Submission of Revisions**

Authors submitting a revised manuscript after review are asked to include the following:
A rebuttal letter, indicating point-by-point how they have addressed the comments raised by the reviewers. If the authors disagree with any of the points raised, they can decline to change the manuscript provided they justify their decision in the rebuttal letter.

A marked-up version of the manuscript that highlights changes made in response to the reviewers' comments.

A 'clean' (non-highlighted) version of the manuscript.

**POST-ACCEPTANCE**

Once a manuscript is accepted, the corresponding author must complete and sign a Licence to Publish form on behalf of all authors and return it to the editorial office. Failure to promptly return the form will delay publication.

Springer Nature does not require authors of original research papers to assign copyright of their published contributions. Authors grant Springer Nature an exclusive licence to publish, in return for which they can re-use their papers in their future printed work. Springer Nature's [author licence page](#) provides details of the policy.

**Standard Publication**

Manuscripts published under the standard method of publication will be behind a paywall, requiring readers to pay to view the article, either via their institutional or personal subscription or on a pay-per-view basis. Please click here for a copy of the standard Licence to Publish form.

Government employees from the United States and the UK are required to sign and submit the relevant form below:

- [US Government Employee Licence to Publish form](#)
- [UK Government Employee Licence to Publish form](#)

**Open Access Publication (gold open access)**

Upon acceptance, authors can indicate whether they wish to pay an optional article processing charge (APC) for their article to be made open access online immediately upon publication. Open access articles are published under Creative Commons licenses, which allow authors to retain copyright to their work while making it open to readers.

To facilitate self-archiving Springer Nature deposits open access articles in PubMed Central and Europe PubMed Central on publication. Authors are also permitted to post the final, published PDF of their article on a website, institutional repository or other free public server, immediately on publication.

Visit our open research site for further information about licenses, APCs, and our free OA funding support service:

- [About Creative Commons licensing](#)
- [Creative Commons license options and article processing charges (APCs) for Spinal Cord](#)
- [APC payment FAQs](#)
- [Help in identifying funding for APCs](#)
- [Editorial process for OA publication in hybrid journals](#)
- [Self-archiving and deposition of papers published OA](#)

If authors opt to publish via the open access route then the corresponding author must complete and sign the [Article Processing Charge (APC) payment form](#) and an [open access License to Publish (LTTP) form](#) on behalf of all authors, and return these to the editorial office. These forms will be provided upon acceptance of a manuscript. Failure to promptly return forms will delay publication.

Government employees from the [United States](#) and [UK](#) are required to sign and submit the relevant government open access license to publish form.

Please note with regards to payment that usual credit terms are 30 days from receipt of invoice. Failure to pay an invoice within the stated credit term may result in the Open Access status of the paper being rescinded, with the paper being placed behind the paywall. Authors may also be subject to such penalties as restrictions on their ability to publish with Springer Nature in the future, involvement of a third party debt collection agency and legal proceedings.

**Compliance with open access mandates**

Springer Nature’s open access journals allow authors to comply with all funders’ open access policies worldwide. Authors may need to take specific actions to achieve compliance with funder and institutional open access mandates.

Learn more about [open access compliance](#).

**Waiver of institutional open access policies**

Please note that Harvard University FAS, MIT, Princeton, UCSF, University of Hawaii at Manoa, California Institute of Technology (Caltech) and the Georgia Institute of Technology have enacted Open Access policies that conflict with our own policy for articles published via the subscription route. If any corresponding or contributing authors are from these institutions, they will need to provide a waiver from the institution of every affected author, which can be obtained from the institution. This waiver should be submitted at the same time as the Licence to Publish form. This requirement does not apply to articles published via the open access route.

**Self-archiving and manuscript deposition (green open access)**

Authors of original research articles are encouraged to submit the author’s version of the accepted paper (the unedited manuscript) to a repository for public release six months after publication. Springer Nature also offers a free, opt-in Manuscript Deposition Service for original research articles in order to help authors fulfil funder and institutional mandates.

Learn more about [self-archiving and manuscript deposition](#).

**Proofs**

The corresponding author will receive an e-mail containing a URL linking to the proofs of the manuscript. Proof corrections must be returned within 48 hours of receipt. Failure to do so may result in
delayed publication. Extensive corrections cannot be made at this stage.

**Advance Online Publication**

The final version of the manuscript is published online in advance of print (AOP). AOP represents the official version of the manuscript and will subsequently appear unchanged, in print.

**COSTS**

**Open Access Publication**

Spinal Cord levies the following Article-Processing Charges (APC) per article accepted for publication (plus VAT where applicable):

<table>
<thead>
<tr>
<th>LICENCE TYPE</th>
<th>ORIGINAL ARTICLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Creative Commons Attribution 4.0 International Licence</td>
<td>£2,200 / $3,300 / €2,700</td>
</tr>
<tr>
<td>Creative Commons Attribution-Noncommercial-Share Alike 4.0 International Licence</td>
<td>£2,000 / $3,000 / €2,400</td>
</tr>
<tr>
<td>Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 International Licence</td>
<td>£2,000 / $3,000 / €2,400</td>
</tr>
</tbody>
</table>

**Colour Charges**

There is a charge if authors choose to publish their figures in colour in print publication (which includes the online PDF):

<table>
<thead>
<tr>
<th>Number of colour illustrations</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7+</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cost</td>
<td>£573</td>
<td>£852</td>
<td>£1,132</td>
<td>£1,303</td>
<td>£1,473</td>
<td>£1,619</td>
<td>£146</td>
</tr>
<tr>
<td>Rest of world</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>USA</td>
<td>£883</td>
<td>$1,313</td>
<td>$1,745</td>
<td>$2,007</td>
<td>$2,270</td>
<td>$2,496</td>
<td>$226</td>
</tr>
</tbody>
</table>

(VAT or local taxes will be added where applicable)

Colour charges will not apply to authors who choose to pay an article processing charge to make their paper open access.

**Offprints**

Offprints may be ordered on the form accompanying the proofs. Charges are necessarily higher if orders for offprints are received after the issue has gone to press.

**EDITORIAL POLICIES**

**Duplicate Publication**

Papers must be original and not published or submitted for publication elsewhere. This rule also applies to non-English language publications. Springer Nature allows and encourages prior publication on recognized community preprint servers for review by other scientists before formal submission to the journal. The details of the preprint server concerned and any accession numbers should be included in the cover letter accompanying manuscript submission. This policy does not extend to preprints available to the media or that are otherwise publicized outside the scientific community before or during the submission and consideration process.

**Permissions**

If a table or figure has been published before, the authors must obtain written permission to reproduce the material in both print and electronic formats from the copyright owner and submit it with the manuscript. This follows for quotes, illustrations and other materials taken from previously published works not in the public domain. The original source should be cited in the figure caption or table footnote. Colour figures can be reproduced if necessary, but the authors will be expected to contribute towards the cost of publication. A quote will be supplied upon acceptance of the paper.

**Clinical Trials**

As defined by the International Committee of Medical Journal Editors (ICMJE), a clinical trial is any research project that prospectively assigns human participants to intervention with or without a comparison group to study the cause-and-effect relationship between a medical intervention and a health outcome. A medical intervention is any use intended to modify a health
outcome and includes but is not limited to drugs, surgical procedures, devices, behavioural treatments, and process-of-care changes. A trial must have at least one prospectively assigned concurrent control and/or comparison group in order to trigger the requirement for registration. Nonrandomized trials are not exempt from the registration requirement if they meet the above criteria.

When reporting experiments on human participants, authors must indicate whether the procedures were in accordance with the ethical standards of the responsible committee on human experimentation (institutional or regional) or with the Helsinki Declaration of 1975 (as revised in 1983). Include Institutional Review Board or Animal Care and Use Committee approvals. All clinical trials must be registered in a public registry prior to submission. The journal will be introducing in the near future, the requirement that trials are registered prior to the commencement of recruitment. The journal follows the trials registration policy of the ICMJE (www.icmje.org) and considers only trials that have been appropriately registered before submission, regardless of when the trial closed to enrolment. Acceptable registries must meet the following ICMJE requirements:

- be publicly available, searchable, and open to all prospective registrants
- have a validation mechanism for registration data
- be managed by a not-for-profit organization

Examples of registries that meet these criteria include:

- the registry sponsored by the United States National Library of Medicine (www.clinicaltrials.gov);
- the International Standard Randomized Controlled Trial Number Registry (www.controlled-trials.com);
- the Australian and New Zealand Clinical Trials registry (http://www.anzctr.org.au/);

The trial registry number for eligible papers will be collected during the submission process.

**Reporting guidelines**

Studies must adhere to the reporting guidelines as outlined by the Equator Network (http://www.equator-network.org/). Where appropriate the accompanying checklists need to be submitted with the manuscript to indicate where in the manuscript each item is reported. These include:

- the CONSORT guidelines for randomised trials.
- the STROBE guidelines for observational studies.
- the PRISMA guidelines for systematic reviews.
- the STARD guidelines for diagnostic/prognostic studies.
- the ARRIVE guidelines for pre-clinical animal studies.

Springer Nature endorses the toolkits and guidelines produced by the Committee on Publication Ethics (COPE): http://publicationethics.org/

**Conflicts of Interest**

In the interests of transparency and to help readers form their own judgments of potential bias, authors must declare whether or not there are any competing financial interests in relation to the work described. This information must be included in the cover letter and on the title page of the manuscript. In cases where the authors declare a competing financial interest, a statement to that effect is published as part of the article. If no such conflict exists, the statement will simply read that the authors have nothing to disclose.

For the purposes of this statement, competing interests are defined as those of a financial nature that, through their potential influence on behaviour or content, or from perception of such potential influences, could undermine the objectivity, integrity or perceived value of a publication. They can include any of the following:

- Funding: Research support (including salaries, equipment, supplies, reimbursement for attending symposia, and other expenses) by organizations that may gain or lose financially through this publication. The role of the funding body in the design of the study, collection and analysis of data and decision to publish should be stated.
- Employment: Recent (while engaged in the research project), present or anticipated employment by any organization that may gain or lose financially through this publication.
- Personal financial interests: Stocks or shares in companies that may gain or lose financially through publication; consultation fees or other forms of remuneration from organizations that may gain or lose financially; patents or patent applications whose value may be affected by publication.

It is difficult to specify a threshold at which a financial interest becomes significant, but note that many US universities require faculty members to disclose interests exceeding $10,000 or 5% equity in a company. Any such figure is arbitrary, so we offer as one possible practical alternative guideline: "Declare all interests that could embarrass you were they to become publicly known after your work was published." We do not consider diversified mutual funds or investment trusts to constitute a competing financial interest.

The statement must be explicit and unambiguous describing any potential conflicts of interest, or lack thereof, for any of the authors as it relates to the subject of the manuscript. Examples include “Dr. Smith receives compensation as a consultant for XYZ Company,” “Dr. Jones and Dr. Smith have financial holdings in ABC Company,” or “Dr. Jones owns a patent on the diagnostic device described in this report.” These statements acknowledging or denying conflicts of interest must be included in the manuscript under the heading Conflicts of Interest. The Conflicts of Interest disclosure appears in the cover letter, in the manuscript submission process and before the References section in the manuscript.

Following the Conflicts of Interest heading, there must be a listing for each author, detailing the professional services relevant to the submission. Neither the precise amount received from each entity nor the aggregate income from these sources needs to be provided. Professional services include any activities for which the individual is, has been, or will be compensated with cash, royalties, fees, stock or stock options in exchange for work performed, advice or counsel provided, or for other services related to the author’s professional knowledge and skills. This would include, but not necessarily be limited to, the identification of organizations from which the author received contracts or in which he or she holds an equity stake if professional services were provided in conjunction with the transaction.

Revised 26/06/2017
Examples of declarations are:

- **Conflicts of interest.**
  The authors declare no conflicts of interest.
- **Conflicts of interest.**
  Dr Caron’s work has been funded by the NIH. He has received compensation as a member of the scientific advisory board of Acadia Pharmaceutical and owns stock in the company. He also has consulted for Lundbeck and received compensation. Dr Rothman and Dr Jensen declare no potential conflicts of interest.

**Communication with the Media**

Material submitted must not be discussed with the media. We reserve the right to halt the consideration or publication of a paper if this condition is broken. If a paper is particularly newsworthy, the press release will be sent to our list of journalists in advance of publication with an embargo that forbids any coverage of the manuscript, or the findings of the manuscript, until the time and date clearly stated. Authors whose papers are scheduled for publication may also arrange their own publicity (for instance through their institution’s press offices), but they must strictly adhere to our press embargo and are advised to coordinate their own publicity with our press office.

**Communication Between Scientists**

We encourage communication between scientists. Authors can communicate with other researchers as much as they wish, whether on a recognized community preprint server, by discussion at scientific meetings or by online collaborative sites such as wikis, but authors must not discuss manuscripts with the press prior to publication (beyond a formal presentation, if at a conference).

**Pre- and Post-Submissions**

Authors are welcome to post pre-submission versions or the original submitted version of the manuscript on a personal blog, a collaborative wiki or a recognized preprint server (such as ArXiv) at any time (but not versions of their manuscripts that have not yet been through the full editorial process including type setting). For subscribed content, the accepted version of the manuscript, following the review process, may only be posted 6 months after the paper is published in SC and SC Series & Cases. A publication reference and URL to the published version on the journal website must be provided on the first page of the postprint. The published version — copyedited and in the individual journal format — may not be posted on any website or preprint server.

For open access content published under a creative commons license, authors can replace the submitted version with the final published version at publication as long as a publication reference and URL to the published version on the journal website are provided.

**Authorship**

Requirements for all categories of articles should conform to the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals,” developed by the ICMJE (www.icmje.org).

Each author must have contributed sufficiently to the intellectual content of the submission. The corresponding author should list all authors and their contributions to the work. Any changes to the author list after submission, such as a change in the order of the authors, or the deletion or addition of authors, must be approved by a signed letter from every author. The corresponding author must confirm that he or she has had full access to the data in the study and final responsibility for the decision to submit for publication. To qualify as a contributing author, one must meet all of the following criteria:

- Conceived and/or designed the work that led to the submission, acquired data, and/or played an important role in interpreting the results.
- Drafted or revised the manuscript.
- Approved the final version.

Contributions by individuals who made direct contributions to the work but do not meet all of the above criteria should be noted in the Acknowledgments section of the manuscript. Medical writers and industry employees can be contributors. Their roles, affiliations, and potential conflicts of interest should be included in the author list or noted in the Acknowledgments and/or Contributors section concurrent with their contribution to the work submitted. Signed statements from any medical writers or editors declaring that they have given permission to be named as an author, as a contributor, or in the Acknowledgments section is also required. Failure to acknowledge these contributors can be considered inappropriate, which conflicts with the journal’s editorial policy.

**Correspondence with the Journal**

One author is designated the contact author for matters arising from the manuscript (eg. material requests and technical comments). It is this author’s responsibility to inform all co-authors of matters arising and to ensure such matters are dealt with promptly. Before submission, the corresponding author must ensure that all authors are included on the author list, the author order has been agreed upon by all authors, and all authors are aware that the manuscript is being submitted. After acceptance for publication, proofs are e-mailed to this corresponding author who should circulate the proofs to all co-authors and coordinate all suggested corrections.

**Plagiarism and Fabrication**

Plagiarism is when an author attempts to pass off someone else’s work as his or her own. Duplicate publication, sometimes called self-plagiarism, occurs when an author reuses substantial parts of his or her own published work without providing the appropriate references.

Springer Nature Journals use CrossCheck, a plagiarism detection software tool, to identify instances of overlapping and similar text in submitted manuscripts. CrossCheck is a multi-publisher initiative to screen published and submitted content for originality. To find out more about CrossCheck visit www.crossref.org/crosscheck.html.

Manuscripts found to have substantial text that has been plagiarised will be rejected without the option of resubmitting a similar manuscript, and the authors will be provided with one warning. If any author that is warned subsequently submits a second manuscript which also contains text that has been plagiarised, then one or all of the following will happen:

- authors’ institutes and/or funding agencies will be notified.
• the ISCoS Executive and Council will be notified
• authors will be banned from publishing in Spinal Cord for a period of time (or indefinitely if serious)
• authors will not be able to serve on the Editorial Board of Spinal Cord
• all manuscripts subsequently submitted by any of the authors will be carefully checked for plagiarism

If a case of plagiarism comes to light after a paper is published, the Journal will conduct a preliminary investigation, utilising the guidelines of the Committee on Publication Ethics. If plagiarism is proven, the Journal will contact the author's institute and funding agencies as appropriate. The paper containing the plagiarism may also be formally retracted or subject to correction.

Image Integrity and Standard

Images submitted with a manuscript for review should be minimally processed (for instance, to add arrows to a micrograph). Authors should retain their unprocessed data and metadata files, as editors may request them to aid in manuscript evaluation. If unprocessed data is unavailable, manuscript evaluation may be stalled until the issue is resolved.

A certain degree of image processing is acceptable for publication but the final image must correctly represent the original data and conform to community standards. The guidelines below will aid in accurate data presentation at the image processing level:

• Authors should list all image acquisition tools and image processing software packages used. Authors should document key image-gathering settings and processing manipulations in the Methods section.
• Images gathered at different times or from different locations should not be combined into a single image, unless it is stated that the resultant image is a product of time-averaged data or a time-lapse sequence. If juxtaposing images are essential, the borders should be clearly demarcated in the figure and described in the legend.
• Touch-up tools, such as cloning and healing tools in Photoshop, or any feature that deliberately obscures manipulations, is to be avoided.
• Processing (such as changing brightness and contrast) is appropriate only when it is applied equally across the entire image and is applied equally to controls. Contrast should not be adjusted so that data disappear. Excessive manipulations, such as processing to emphasize one region in the image at the expense of others (for example, through the use of a biased choice of threshold settings), is inappropriate, as is emphasizing experimental data relative to the control.

For gels and blots, positive and negative controls, as well as molecular size markers, should be included on each gel and blot – either in the main figure or an expanded data supplementary figure. The display of cropped gels and blots in the main paper is encouraged if it improves the clarity and conciseness of the presentation. In such cases, the cropping must be mentioned in the figure legend.

• Vertically sliced gels that juxtapose lanes that were not contiguous in the experiment must have a clear separation or a black line delineating the boundary between the gels.
• Cropped gels in the paper must retain important bands.
• Cropped blots in the body of the paper should retain at least six band widths above and below the band.
• High-contrast gels and blots are discouraged, as overexposure may mask additional bands. Authors should strive for exposures with grey backgrounds. Immunoblots should be surrounded by a black line to indicate the borders of the blot if the background is faint.
• For quantitative comparisons, appropriate reagents, controls and imaging methods with linear signal ranges should be used.

Microscopy adjustments should be applied to the entire image. Threshold manipulation, expansion or contraction of signal ranges and the altering of high signals should be avoided. If ‘pseudo-colouring’ and nonlinear adjustment (for example ‘gamma changes’) are used, this must be disclosed. Adjustments of individual colour channels are sometimes necessary on ‘merged’ images, but this should be noted in the figure legend. We encourage inclusion of the following with the final revised version of the manuscript for publication:

• In the Methods section, specify the type of equipment (microscopes/objective lenses, cameras, detectors, filter model and batch number) and acquisition software used. Although we appreciate that there is some variation between instruments, equipment settings for critical measurements should also be listed.
• The display lookup table (LUT) and the quantitative map between the LUT and the bitmap should be provided, especially when rainbow pseudo-colour is used. It should be stated if the LUT is linear and covers the full range of the data.
• Processing software should be named and manipulations indicated (such as type of deconvolution, three-dimensional reconstructions, surface and volume rendering, ‘gamma changes’, filtering, thresholding and projection).
• Authors should state the measured resolution at which an image was acquired and any downstream processing or averaging that enhances the resolution of the image.

Research Data Policy

We strongly encourage authors to make available to readers all datasets on which the conclusions of a paper rely. We encourage authors to ensure that their datasets are either deposited in publicly available repositories (where available and appropriate) or presented in the main manuscript or additional supporting files whenever possible. Where one does not exist, the information must be made available to referees at submission and to readers promptly upon request. Any restrictions on material availability or other relevant information must be disclosed in the manuscript’s Methods section and should include details of how materials and information may be obtained.

Please see the journals guidelines on Research Data policy here.

Sequences, Structures and “Omics”

Papers reporting protein or DNA sequences and molecular structures will not be accepted without an accession number to Genbank/EMBL/DBJ/SWISS-PROT, ProteinDataBank, or other publicly available database in general use in the field that gives free access to researchers from the date of publication.

Revised 26/06/2017
Authors of papers describing structures of biological macromolecules must provide experimental data upon the request of Editor-in-Chief if they are not already freely accessible in a publicly available database such as Protein Data Bank, Biological Magnetic Resonance Database, or Nucleic Acid Database.

Human and Other Animal Experiments

For primary research manuscripts reporting experiments on live vertebrates and/or higher invertebrates, the corresponding author must confirm that all experiments were performed in accordance with relevant guidelines and regulations. The manuscript must include in the Supplementary Information (methods) section (or, if brief, within of the print/online article at an appropriate place), a statement identifying the institutional and/or licensing committee approving the experiments, including any relevant details regarding animal welfare, patient anonymity, drug side effects and informed consent.

For experiments involving human participants, authors must identify the committee approving the experiments, and include with their submission a statement confirming that informed consent was obtained from all participants.

Biosecurity Policy

The Editor-in-Chief may seek advice about submitted papers not only from technical reviewers but also on any aspect of a paper that raises concerns. These may include, for example, ethical issues or issues of data or materials access. Occasionally, concerns may also relate to the implications to society of publishing a paper, including threats to security. In such circumstances, advice will usually be sought simultaneously with the technical peer-review process. As in all publishing decisions, the ultimate decision whether to publish is the responsibility of the Editor-in-Chief of Spinal Cord.

Peer Review

Manuscripts sent out for peer review are evaluated by two to four independent reviewers (or more). Authors are welcome to suggest independent reviewers to evaluate their manuscript, as well as request individuals or laboratories. Authors may also ask to specifically exclude individuals or institutions from the review process. All recommendations are considered by the Editor-in-Chief, but at his/her discretion. To expedite the review process, only papers that seem most likely to meet editorial criteria are sent for external review. Papers judged by the Editor-in-Chief to be of insufficient general interest or otherwise inappropriate are rejected promptly without external review. The Editor-in-Chief makes one of the following decisions on papers sent out to review based on the reviewers’ comments:

- **Accept**, with or without editorial revisions.
- **Revise**, with the author addressing concerns raised by the reviewers before a final decision is reached.
- **Reject with the option to resubmit** if further work might justify a resubmission.
- **Reject without the option to resubmit** if the manuscript is of specialist or local interest only, lacks novelty, does not sufficiently contribute to a conceptual advancement or has major technical, methodological and/or interpretational problems.

Anonymity and Confidentiality

All details about submitted manuscripts are kept confidential and no comments are issued to outside parties or organizations about manuscripts under consideration or manuscript that are rejected. The Editor-in-Chief can only make public comments on the content and the journals evaluation of a published article.

Reviewers’ identities are not released to authors unless reviewers specifically ask to be identified. We ask reviewers not to identify themselves to authors without the Editor-in-Chief’s knowledge. If reviewers wish to reveal their identities while the manuscript is under consideration, this should be done via the Editor-in-Chief; if this is not practicable, then authors need to inform the Editor-in-Chief as soon as possible after the identity of a reviewer has been revealed. We deplore any attempt by authors to confront reviewers or try to determine their identities. Our own policy is to neither confirm nor deny any speculation about reviewers’ identities, and we encourage reviewers to adopt a similar policy.

Upon accepting an invitation to evaluate a manuscript, reviewers must keep the manuscript and associated data confidential, and not redistribute them without the journal’s permission. If a reviewer asks a colleague to assist in assessing a manuscript, confidentiality must be ensured and their names must be provided to the journal with the final report.

Selecting Peer Reviewers

Reviewer selection is critical to the publication process, and based on many factors including expertise, reputation, and specific recommendations. A reviewer may decline the invitation to evaluate a manuscript where there is a perceived conflict of interest (financial or otherwise).

Correction and Retraction Process

Content published as Advance Online Publication (AOP) is final and cannot be amended. The online and print versions are both part of the published record hence the original version must be preserved and changes to the paper should be made as a formal correction. If an error is noticed in an AOP article, a correction should accompany the article when it is published in print. An HTML (or full-text) version of the correction will also be created and linked to the original article. If the error is found in an article after print publication the correction will be published online and in the next available print issue.

Please note the following categories of corrections to print and online versions of peer reviewed content:

- **Erratum.** Notification of an important error made by the journal that affects the publication record or the scientific integrity of the paper, or the reputation of the authors or the journal.
- **Corrigendum.** Notification of an important error made by the author that affects the publication record or the scientific integrity of the paper, or the reputation of the authors or the journal.
- **Retraction.** Notification of invalid results. All co-authors must sign a retraction specifying the error and stating briefly how the conclusions are affected.

Decisions about corrections are made by the Editor-in-Chief (sometimes with peer-reviewers’ advice) and this sometimes involves author consultation. Requests to make corrections that do

Revised 26/06/2017
not affect the paper in a significant way or impair readers’ understanding of the contribution (a spelling mistake or grammatical error, for example) are not considered. In cases where co-authors disagree about a correction, the editors will take advice from independent peer-reviewers and impose the appropriate correction, noting the dissenting author(s) in the text of the published version.

FURTHER INFORMATION

For inquiries related to submission requirements, please contact the editorial office. For inquiries related to advertising, subscriptions, permissions, papers in production or publishing a supplement, please contact the publisher’s office.

References cites in these guidelines